Alnylam Pharmace. buy StockNews.com
Start price
06.05.23
/
50%
€193.40
Target price
06.05.24
-
Performance (%)
-26.81%
End price
07.05.24
€141.55
Summary
This prediction ended on 07.05.24 with a price of €141.55. The price of Alnylam Pharmace. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -26.81%. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -0.982% | -0.982% | -10.108% | 31.325% |
| iShares Core DAX® | 1.352% | 2.740% | 7.868% | 51.841% |
| iShares Nasdaq 100 | 3.277% | 6.507% | 41.460% | 93.775% |
| iShares Nikkei 225® | 7.434% | 17.832% | 69.101% | 79.073% |
| iShares S&P 500 | 1.702% | 3.099% | 27.307% | 67.281% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten